Araştırma Makalesi
BibTex RIS Kaynak Göster

Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors

Yıl 2017, Cilt: 4 Sayı: 3, 23 - 26, 31.03.2017

Tugba Gur Gulsen Enterili Necip Pirincci Canan Demir Halit Demir Mehmet Kaba Huseyin Eren

https://doi.org/10.17546/msd.292489

Öz





Objective:
Reactive oxygen species (ROS) and antioxidant capacity have been implicated
in the pathogenesis of various diseases, and cancers. Oxidative stress can
cause tumor angiogenesis and may be carcinogenic. However, the relationship
between antioxidant capacity and various cancers has been researched in
several clinical trials.


Materials and Methods: In this
study, we aimed to identify serum Nitric Oxide (NO), Arylesterase (ARE) and
paraoxonase (PON) activities in patients with renal tumors. Serum ARE, PON and
NO levels were measured by spectrophotometer.


Results:
Increased
activity of serum nitric oxide (NO) was determined in cancer group. Serum
Arylesterase (ARE) were significantly lower in the patient group than the
control group. Increased activity of Serum paraoxonase (PON) were detected in
the control group (p < 0.05).


Conclusion: Our
results indicates that Nitric oxide (NO), arylesterase (ARE) and paraoxonase
(PON) activities may play an important role in the pathogenesis of renal cell
cancer.

Anahtar Kelimeler

ARE NO PON Arylesterase Nitric Oxide Serum paraoxonase Renal tumor

Kaynakça

  • 1. Curti BD, Renal cell carcinoma. JAMA,. 292, 97–100 (2004).
  • 2. Chow WH, Devesa SS, and Warren JL et al., JAMA, 281,1628–31(1999).
  • 3. Dhote R, Pellicer-Coeuret M, Thiounn N, et al., BJU Int.86: 20–7 (2000).
  • 4. McLaughlin JK, Blot WJ, Devesa SS et al., Renal cancer. In: Schottenfeld D and Fraumeni JF (eds) Cancer Epidemiology and Prevention. New York, NY: Oxford University Press, pp. 1142–55 (1996).
  • 5. Templar J, Kon SP, Milligan TP, et al., Nephrology Dialysis Transplantation 14, 946–51(1999).
  • 6. Batcioglu K, Mehmet N, Ozturk IC, et al., Cancer Invest. 24, 18–21(2006).
  • 7. Nishikawa M, Cancer Lett, 266, 53–9 (2008).
  • 8. Ray G, Batra S, Shukla NK et al., Breast Cancer Res Treat.59:163–70 (2000).
  • 9. Wang GQ, Dawsey SM, and Li Y, Cancer Epidemiology, Biomarkers and Prevention, 3,161–66 (1994).
  • 10. Oberley LW, and Buettner GR, Cancer Research 39: 1141–9 (1979).
  • 11. Gecit I, Aslan M, Gunes M, et al., J Cancer Res, Clin, Oncol., 138: 739–43 (2012).
  • 12. Cortas NK, and Wakid NW. Clin. Chem., 36, 1440-1443 (1990).
  • 13. Erel O. Clin. Biochem, 37, 112–229 (2004).
  • 14. Erel O, Clin. Biochem, 38, 1103–1111 (2005).
  • 15. Gülçin I, Oktay M, Küfrevioǧlu, ÖI, and Aslan A, Journal of Ethnopharmacology, 79 (3), 325-329 (2002).
  • 16. Jaruga P, Zastawny TH, Skokowski J, et al., FEBS Lett. 341(1),59-64 (1994).
  • 17. Sun Y, and Oberley LW, Free Radical Free Radic, Biol, Med. 21: 335–48 (1996).
  • 18. Blackburn RV, Spitz DR, Liu X, et al., Free Radic Biol, Med, 26, 419–30 (1999). 9) Toyokuni S, Okamoto K, Yodoi J, et al., FEBS Lett.16, 3581–3 (1995).
  • 19. Meyer TE, Liang HQ, Buckley AR, et al., International Journal of Cancer 3: 55–63 (1998).
  • 20. Mantovani G, MaccioA, Madeddu C, et al., International Journal of Cancer 98: 84–91 (2002).
  • 21. Szatrowski TP, and Nathan CF, Cancer Res. 51, 794–8 (1991).
  • 22. Marnett LJ, Mutat Res 424, 83–95 (1999).
  • 23. Seven A, Civelek S, Inci E, et al., Clinical Biochemistry, 32, 369–73 (1999).
  • 24. Marnett LJ, Carcinogenesis. 21, 361–370 (2000).
  • 25. Vo TKO, Druez C, Delzenne N, et al., Carcinogenesis. 9(11), 2009–2013 (1988).
  • 26. Corrocher R, Casaril M, Bellisola G, et al., Cancer, 58(8), 1658–62 (1986).
  • 27. Nakada T, Akiya T, Koike H et al., Eur Urol, 14(1), 50–5 (1988).
  • 28. Ozturk HS, Karaayvaz M, Kacmaz M, et al., Cancer Biochemistry Biophysics, 16, 157–168 (1998).
  • 29. Ferraris AM, Rolfo M, Mangerini R, et al., Am J Hematol., 47, 237–278 (1994).
  • 30. Farber CM, Kanganis DN, Liebes LF, et al., Br J Haematol 72, 32–35 (1989).

Yıl 2017, Cilt: 4 Sayı: 3, 23 - 26, 31.03.2017

Tugba Gur Gulsen Enterili Necip Pirincci Canan Demir Halit Demir Mehmet Kaba Huseyin Eren

https://doi.org/10.17546/msd.292489

Öz

Kaynakça

  • 1. Curti BD, Renal cell carcinoma. JAMA,. 292, 97–100 (2004).
  • 2. Chow WH, Devesa SS, and Warren JL et al., JAMA, 281,1628–31(1999).
  • 3. Dhote R, Pellicer-Coeuret M, Thiounn N, et al., BJU Int.86: 20–7 (2000).
  • 4. McLaughlin JK, Blot WJ, Devesa SS et al., Renal cancer. In: Schottenfeld D and Fraumeni JF (eds) Cancer Epidemiology and Prevention. New York, NY: Oxford University Press, pp. 1142–55 (1996).
  • 5. Templar J, Kon SP, Milligan TP, et al., Nephrology Dialysis Transplantation 14, 946–51(1999).
  • 6. Batcioglu K, Mehmet N, Ozturk IC, et al., Cancer Invest. 24, 18–21(2006).
  • 7. Nishikawa M, Cancer Lett, 266, 53–9 (2008).
  • 8. Ray G, Batra S, Shukla NK et al., Breast Cancer Res Treat.59:163–70 (2000).
  • 9. Wang GQ, Dawsey SM, and Li Y, Cancer Epidemiology, Biomarkers and Prevention, 3,161–66 (1994).
  • 10. Oberley LW, and Buettner GR, Cancer Research 39: 1141–9 (1979).
  • 11. Gecit I, Aslan M, Gunes M, et al., J Cancer Res, Clin, Oncol., 138: 739–43 (2012).
  • 12. Cortas NK, and Wakid NW. Clin. Chem., 36, 1440-1443 (1990).
  • 13. Erel O. Clin. Biochem, 37, 112–229 (2004).
  • 14. Erel O, Clin. Biochem, 38, 1103–1111 (2005).
  • 15. Gülçin I, Oktay M, Küfrevioǧlu, ÖI, and Aslan A, Journal of Ethnopharmacology, 79 (3), 325-329 (2002).
  • 16. Jaruga P, Zastawny TH, Skokowski J, et al., FEBS Lett. 341(1),59-64 (1994).
  • 17. Sun Y, and Oberley LW, Free Radical Free Radic, Biol, Med. 21: 335–48 (1996).
  • 18. Blackburn RV, Spitz DR, Liu X, et al., Free Radic Biol, Med, 26, 419–30 (1999). 9) Toyokuni S, Okamoto K, Yodoi J, et al., FEBS Lett.16, 3581–3 (1995).
  • 19. Meyer TE, Liang HQ, Buckley AR, et al., International Journal of Cancer 3: 55–63 (1998).
  • 20. Mantovani G, MaccioA, Madeddu C, et al., International Journal of Cancer 98: 84–91 (2002).
  • 21. Szatrowski TP, and Nathan CF, Cancer Res. 51, 794–8 (1991).
  • 22. Marnett LJ, Mutat Res 424, 83–95 (1999).
  • 23. Seven A, Civelek S, Inci E, et al., Clinical Biochemistry, 32, 369–73 (1999).
  • 24. Marnett LJ, Carcinogenesis. 21, 361–370 (2000).
  • 25. Vo TKO, Druez C, Delzenne N, et al., Carcinogenesis. 9(11), 2009–2013 (1988).
  • 26. Corrocher R, Casaril M, Bellisola G, et al., Cancer, 58(8), 1658–62 (1986).
  • 27. Nakada T, Akiya T, Koike H et al., Eur Urol, 14(1), 50–5 (1988).
  • 28. Ozturk HS, Karaayvaz M, Kacmaz M, et al., Cancer Biochemistry Biophysics, 16, 157–168 (1998).
  • 29. Ferraris AM, Rolfo M, Mangerini R, et al., Am J Hematol., 47, 237–278 (1994).
  • 30. Farber CM, Kanganis DN, Liebes LF, et al., Br J Haematol 72, 32–35 (1989).
Toplam 30 adet kaynakça vardır.

Ayrıntılar

Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma Makalesi
Yazarlar

Tugba Gur

Gulsen Enterili Bu kişi benim

Necip Pirincci

Canan Demir Bu kişi benim

Halit Demir

Mehmet Kaba

Huseyin Eren Bu kişi benim

Yayımlanma Tarihi 31 Mart 2017
Yayımlandığı Sayı Yıl 2017 Cilt: 4 Sayı: 3

Kaynak Göster

APA Gur, T., Enterili, G., Pirincci, N., Demir, C., vd. (2017). Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors. Medical Science and Discovery, 4(3), 23-26. https://doi.org/10.17546/msd.292489
AMA Gur T, Enterili G, Pirincci N, Demir C, Demir H, Kaba M, Eren H. Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors. Med Sci Discov. Mart 2017;4(3):23-26. doi:10.17546/msd.292489
Chicago Gur, Tugba, Gulsen Enterili, Necip Pirincci, Canan Demir, Halit Demir, Mehmet Kaba, ve Huseyin Eren. “Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors”. Medical Science and Discovery 4, sy. 3 (Mart 2017): 23-26. https://doi.org/10.17546/msd.292489.
EndNote Gur T, Enterili G, Pirincci N, Demir C, Demir H, Kaba M, Eren H (01 Mart 2017) Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors. Medical Science and Discovery 4 3 23–26.
IEEE T. Gur, “Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors”, Med Sci Discov, c. 4, sy. 3, ss. 23–26, 2017, doi: 10.17546/msd.292489.
ISNAD Gur, Tugba vd. “Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors”. Medical Science and Discovery 4/3 (Mart 2017), 23-26. https://doi.org/10.17546/msd.292489.
JAMA Gur T, Enterili G, Pirincci N, Demir C, Demir H, Kaba M, Eren H. Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors. Med Sci Discov. 2017;4:23–26.
MLA Gur, Tugba vd. “Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors”. Medical Science and Discovery, c. 4, sy. 3, 2017, ss. 23-26, doi:10.17546/msd.292489.
Vancouver Gur T, Enterili G, Pirincci N, Demir C, Demir H, Kaba M, Eren H. Investigation of Serum Enzyme Activity of Nitric Oxide (NO), Arylesterase (ARE) and Paraoxanase (PON) in Renal Tumors. Med Sci Discov. 2017;4(3):23-6.
 Kapak Resmi İndir